Formative—Onyx Pharmaceuticals 2004 Annual Report:

		Contact Us	Sitemap	Workroom







Investor Relations Sunesis Threshold United Commercial Bank (UCBH) Netflix Fair, Isaac Chiron Onyx Barra Solectron PeopleSoft ALZA Caliper Technologies Aradigm ProBusiness Protein Design Labs Union Bank Foundation Sangamo BioSciences The Asia Foundation The California Endowment BioTime			Formative—Onyx Pharmaceuticals 2004 Annual Report: Onyx Pharmaceuticals is on the brink of commercializing a revolutionary therapy in the war against cancer. By generating a two-pronged response to tumors (cutting off the flow of blood to the fast-growing clusters and derailing these cancer cells’ ability to reproduce itself) Onyx is hoping to make renal and kidney cancer and metastatic melanoma chronic diseases that can be controlled and contained. The three key audiences for this report in its role as a marketing piece are physicians, caregivers, and cancer patient support organizations — each has a story to tell about one of the cancer therapies currently in clinical trials. Unlike most treatments, the Onyx oral delivery, small molecule approach is so carefully targeted that the side effects are minimal and quality of life is not sacrificed — thus the title of this year’s report: “Living with cancer day by day”.